PNOC and Cognitive impairment: For instance, LY2940094 (aka BTRX-246040), a selective and potent NOP antagonist recently developed by Eli Lilly [38], completed phase II clinical trials for the treatment of the major depressive disorder (MDD) and alcohol addiction, Other two NOP receptor antagonists, MK-5757 and JTC-801, entered clinical trials to treat cognitive impairment symptoms associated to schizophrenia and neuropathic pain, respectively (for review see [39]).